Kodiak Sciences Inc.
A clinical-stage biotech developing next-generation medicines for retinal diseases that cause blindness, aiming for longer-lasting anti-VEGF eye injections with candidates like Zenkuda (tarcocimab tedromer) and the bispecific KSI-501. Founded in 2009 as Oligasis and renamed Kodiak Sciences in 2015, the company takes its name from Alaska's mighty Kodiak bear — and fittingly, its Swiss manufacturing plant is called "Ursus," the Latin word for bear.
Granted 300.0K
Granted 88.6K · Sold 60.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Perlroth VictorChairman and CEO, Director · 1 transaction | +14.3% | 2.40M | 300.0K | — | — |
| Borgeson John A.Chief Financial Officer · 9 transactions | +17.8% | 216.0K | 88.6K | — | 60.0K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: -60.0K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.